SCHEMBL24253872

SCHEMBL24253872

O=C1CCCC2(CCN(c3cc(OCC(F)(F)F)ccn3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.36
MGAT2 Q10469 1/20 0.36
TP53 P04637 1/20 0.33
MDM2 Q00987 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
KCNH2 Q12809 1/20 0.33
LTC4S Q16873 1/20 0.33
SCN9A Q15858 2/20 0.32
FFAR4 Q5NUL3 1/20 0.31
LMNA P02545 2/20 0.31
MAPT P10636 2/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
PLA2G7 Q13093 1/20 0.31
CTSS P25774 1/20 0.31
GRIN1 Q05586 2/20 0.31
GRIN2B Q13224 2/20 0.31
RXRA P19793 1/20 0.31
GRIN2A Q12879 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30494534 1.00 ABL1 (0.36) ABL1MGAT2TP53MDM2HCRTR1
SCHEMBL24253949 0.86 ELOVL1 (0.35) MGAT2HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30494526 0.86 ELOVL1 (0.35) MGAT2HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30423539 0.79 KMT2A (0.41) HCRTR1HCRTR2ALDH1A1KMT2A
SCHEMBL24253712 0.79 KMT2A (0.41) HCRTR1HCRTR2ALDH1A1KMT2A
SCHEMBL24253624 0.78 ELOVL1 (0.37) HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30494558 0.78 KCNH2 (0.34) HCRTR1HCRTR2KCNH2LTC4SFFAR4
SCHEMBL24253842 0.78 KCNH2 (0.34) HCRTR1HCRTR2KCNH2LTC4SFFAR4
SCHEMBL24253536 0.77 DPP4 (0.36) HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30494533 0.77 DPP4 (0.36) HCRTR1HCRTR2KCNH2LTC4S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 ABL1 907/4885MGAT2 3978/4885TP53 3877/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 ABL1 907/4885MGAT2 3978/4885TP53 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.